Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Long-Term Extension in Psoriasis
NCT00121615Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2004
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, open-label, single-arm trial of etanercept in psoriasis, sponsored by Amgen. Primary endpoint: Serious Adverse Events. Started Oct 2004; status: completed.
02
Drugs
etanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00121615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121615.